SRR12475135
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.350
- G2M_CHECKPOINT+0.340
- MYC_TARGETS_V1+0.320
- WNT_BETA_CATENIN_SIGNALING+0.230
- PROTEIN_SECRETION+0.210
- SPERMATOGENESIS+0.180
- UV_RESPONSE_DN+0.180
- KRAS_SIGNALING_UP+0.150
- ANGIOGENESIS+0.120
- TGF_BETA_SIGNALING+0.120
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.450
- APICAL_SURFACE-0.400
- ADIPOGENESIS-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- GLYCOLYSIS-0.330
- HYPOXIA-0.330
- ESTROGEN_RESPONSE_EARLY-0.320
- ESTROGEN_RESPONSE_LATE-0.320
- OXIDATIVE_PHOSPHORYLATION-0.320
- FATTY_ACID_METABOLISM-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932838 | — | — | 0.846 |
| 2 | AUR-AG0M-TTP1-A-2-0-R-A741-41 | — | D | 0.844 |
| 3 | ERR2208889 | — | — | 0.819 |
| 4 | s0122214 | — | — | 0.818 |
| 5 | 21e5a870-f00c-4bb9-a1bf-66291ab0d80a | — | — | 0.808 |
| 6 | TCGA-AC-A2QH-01A-11R-A18M-07 | — | D | 0.804 |
| 7 | AUR-AE5H-TTM1-A-1-1-R-A742-41 | — | E | 0.799 |
| 8 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.798 |
| 9 | SRR10899974 | — | — | 0.793 |
| 10 | SRR934948 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |